{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.43","value":"12.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"The OSDI instrument measures vision-related function. The total OSDI score was calculated as (sum of scores for all questions answered\\*100) divided by (total number of questions answered\\*4). The 12 items questionnaire assessed ocular symptoms, visual-related functioning and environmental triggers. Scores ranged from 0 to 100, with higher scores indicating a worse status. Baseline was defined as latest pre-dose assessment (day 1) with a non-missing value, including those from unscheduled visits.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) were administered with 2.5 milligram per kilogram (mg/kg) belantamab mafodotin intravenous (IV) infusion over 30-60 minutes on day 1 of each 21-days cycle. Participants were treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"MEAN","populationDescription":"All treated population","reportingStatus":"POSTED","timeFrame":"Baseline (day 1) Up to 24 months and 21 days","title":"Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score","type":"SECONDARY","unitOfMeasure":"Scores on Scale"}